Abstract
Understanding the scale of the threat posed by SARS-CoV2 B.1.1.529, or Omicron, variant formed a key problem in public health in the early part of 2022. Early evidence indicated that the variant was more transmissible and less severe than previous variants. As the virus was expected to spread quickly through the population of England, it was important that some understanding of the immunological landscape of the country was developed. This paper attempts to estimate the number of people with good immunity to the Omicron variant, defined as either recent infection with two doses of vaccine, or two doses of vaccine with a recent booster dose. To achieve this, we use a process of iterative proportional fitting to estimate the cell values of a contingency table, using national immunisation records and real-time model infection estimates as marginal values. Our results indicate that, despite the increased risk of immune evasion with the Omicron variant, a high proportion of England’s population had good immunity to the virus, particularly in older age groups. However, low rates of immunity in younger populations may allow endemic infection to persist for some time.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authros are funded through the UK Government Department for Health and Social Care grant in aid funding to the UK health Security Agency
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Health Security Agency have provided ethical approval for the research described in this article.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Joseph.shingleton{at}phe.gov.uk
Data Availability
Vaccination data are from the National Immunisation Managment Service (NIMS) database and are not publically avaialable. This is currently managed by NHS England, and appropriate access can be required via https://digital.nhs.uk/coronavirus/vaccinations/training-and-onboarding/point-of-care/national-immunisation-management-service-nims-app. Estimates for COVID-19 infections are taken from the UKHSA-Cambridge COVID-19 infection model. This is currently managed by both the UK Health Security Agency and Cambridge MRC Bio Statistics Unit. The data are not publically available.
